Novo Holdings A/S’s Viridian Therapeutics VRDN Stock Holding History

Novo Holdings A/S’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.2M	Buy	2,135,000 +135,000	+7%	+$2.18M	2.28%	16
2026 Q1	$39.1M	Sell	2,000,000 -380,000	-16%	-$11.3M	3.17%	12
2025 Q4	$74.1M	Hold	2,380,000	–	–	5.75%	7
2025 Q3	$51.4M	Hold	2,380,000	–	–	3.31%	9
2025 Q2	$33.3M	Buy	2,380,000 +129,700	+6%	+$1.76M	2.35%	15
2025 Q1	$30.3M	Buy	2,250,300 +300	+0%	+$5.11K	2.31%	15
2024 Q4	$43.1M	Sell	2,250,000 -135,000	-6%	-$2.94M	2.61%	12
2024 Q3	$54.3M	Buy	2,385,000 +385,000	+19%	+$6.29M	2.69%	10
2024 Q2	$26M	Buy	2,000,000 +900,000	+82%	+$12.5M	1.4%	23
2024 Q1	$19.3M	Buy	+1,100,000	New	+$21.3M	1.33%	24

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Novo Holdings A/S's VRDN Position: Q2 2026 in Review

Novo Holdings A/S increased its Viridian Therapeutics (VRDN) stake by 6.8% in Q2 2026, buying an estimated $2.18M and bringing the position to 2,135,000 shares worth $39.2M. The position accounts for 2.28% of the portfolio, ranked #16.

Novo Holdings A/S first reported a position in VRDN in Q1 2024 and has held it in 10 quarters since. The position peaked at $74.1M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Novo Holdings A/S held 2,135,000 shares of Viridian Therapeutics worth $39.2M as of Q2 2026.
Novo Holdings A/S bought 135,000 Viridian Therapeutics shares in Q2 2026, an estimated $2.18M.
Viridian Therapeutics made up 2.28% of Novo Holdings A/S's portfolio in Q2 2026, its #16 holding.
Novo Holdings A/S first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 10 quarters since.
Novo Holdings A/S's Viridian Therapeutics position peaked at $74.1M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.